Case report: Light-chain amyloidosis responsive to selinexor in combination with daratumumab and dexamethasone (SDd) therapy

Xiaolu Long; Ning An; Chunhui Li; Hui Zhu; Haojie Li; Qiuxia Yu; Yimei Que; Menglei Xu; Zhe Li; Wei Chen; Shuai Wang; Di Wang; Di Wang; Chunrui Li; Chunrui Li

doi:10.3389/fmed.2024.1363805

Frontiers in Medicine (May 2024)

Case report: Light-chain amyloidosis responsive to selinexor in combination with daratumumab and dexamethasone (SDd) therapy

Xiaolu Long,
Ning An,
Chunhui Li,
Hui Zhu,
Haojie Li,
Qiuxia Yu,
Yimei Que,
Menglei Xu,
Zhe Li,
Wei Chen,
Shuai Wang,
Di Wang,
Di Wang,
Chunrui Li,
Chunrui Li

Affiliations

Xiaolu Long: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Ning An: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Chunhui Li: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Hui Zhu: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Haojie Li: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Qiuxia Yu: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Yimei Que: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Menglei Xu: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Zhe Li: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Wei Chen: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Shuai Wang: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Di Wang: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Di Wang: Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China
Chunrui Li: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Chunrui Li: Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China

DOI: https://doi.org/10.3389/fmed.2024.1363805
Journal volume & issue: Vol. 11

Abstract

Read online

The outcome of AL amyloidosis remains poor, particularly in patients with advanced organ involvement which takes long time to recovery. We conducted an observational study of two patients with AL amyloidosis treated with SDd regimen. Both patients successfully achieved significant hematological and organ responses without severe adverse events, and the time to organ response was remarkably shorter than previously reported. Notably, an over 15% reduction in interventricular septal thickness (IVST) was observed in patient#2 within 6 months. Up to now, SDd therapy has not been previously reported in AL amyloidosis and may be a promising option for these patients.

Published in Frontiers in Medicine

ISSN: 2296-858X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Medicine (General)
Website: http://www.frontiersin.org/journals/medicine

About the journal

Abstract

Keywords